Literature DB >> 21925093

Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors.

Peter Lang1, Matthias Pfeiffer, Heiko-Manuel Teltschik, Patrick Schlegel, Tobias Feuchtinger, Martin Ebinger, Thomas Klingebiel, Peter Bader, Paul-Gerhard Schlegel, James Beck, Johann Greil, Rupert Handgretinger.   

Abstract

Lytic activity and recovery of natural killer (NK) cells was monitored in pediatric patients with leukemias (ALL, AML, CML, JMML) and myelodysplastic syndromes after transplantation of T cell depleted stem cells from matched unrelated (n = 18) and mismatched related (haploidentical, n = 29) donors. CD34 + selection with magnetic microbeads resulted in 8 × 10(3)/kg residual T cells. No post-transplant immune suppression was given. NK cells recovered rapidly after transplantation (300 CD56+/μL at day 30, median), whereas T cell recovery was delayed (median: 12 CD3+/μL at day 90). NK activity was measured as specific lysis of K 562 targets several times (mean: 3 assays per patient). Four temporal patterns of lytic activity could be differentiated: consistently low, consistently high, decreasing and increasing activity. Patients with consistently high or increasing activity had significantly lower relapse probability than patients with consistently low or decreasing levels (0.18 vs 0.73 at 2 years, p < 0.05). The subgroup of patients with ALL showed similar results (0.75 vs 0.14 at 2 years, p < 0.05). Speed of T cell recovery had no influence. These data suggest that both achieving and maintaining a high level of NK activity may contribute to prevent relapse. Since NK activity could be markedly increased by in vitro stimulation with Interleukin 2 (IL-2), in vivo administration should be considered.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925093     DOI: 10.1016/j.beha.2011.04.009

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  7 in total

1.  Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.

Authors:  Gerharda H Boerman; Monique M van Ostaijen-ten Dam; Kathelijne C J M Kraal; Susy J Santos; Lynne M Ball; Arjan C Lankester; Marco W Schilham; R Maarten Egeler; Maarten J D van Tol
Journal:  Cancer Immunol Immunother       Date:  2015-02-18       Impact factor: 6.968

2.  CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.

Authors:  L H Xie; M Biondo; S J Busfield; A Arruda; X Yang; G Vairo; M D Minden
Journal:  Blood Cancer J       Date:  2017-06-02       Impact factor: 11.037

3.  Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34+-Selected to CD3/CD19-Depleted Grafts in a Retrospective Multicenter Study.

Authors:  Emilia Salzmann-Manrique; Melanie Bremm; Sabine Huenecke; Milena Stech; Andreas Orth; Matthias Eyrich; Ansgar Schulz; Ruth Esser; Thomas Klingebiel; Peter Bader; Eva Herrmann; Ulrike Koehl
Journal:  Front Immunol       Date:  2018-08-14       Impact factor: 7.561

4.  Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.

Authors:  Muhammad Umair Mushtaq; Moazzam Shahzad; Amna Y Shah; Sibgha Gull Chaudhary; Muhammad U Zafar; Iqra Anwar; Karun Neupane; Ayesha Khalid; Nausheen Ahmed; Rajat Bansal; Ramesh Balusu; Anurag K Singh; Sunil H Abhyankar; Natalie S Callander; Peiman Hematti; Joseph P McGuirk
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

5.  Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia.

Authors:  Matthias Manuel Pfeiffer; Helen Burow; Sabine Schleicher; Rupert Handgretinger; Peter Lang
Journal:  Front Oncol       Date:  2013-04-29       Impact factor: 6.244

Review 6.  The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.

Authors:  Katayoun Rezvani; Rayne H Rouce
Journal:  Front Immunol       Date:  2015-11-17       Impact factor: 7.561

Review 7.  Immune Cells in Cancer Therapy and Drug Delivery.

Authors:  Ceren Eyileten; Kinga Majchrzak; Zofia Pilch; Katarzyna Tonecka; Joanna Mucha; Bartlomiej Taciak; Katarzyna Ulewicz; Katarzyna Witt; Alberto Boffi; Magdalena Krol; Tomasz P Rygiel
Journal:  Mediators Inflamm       Date:  2016-04-24       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.